ABC | Volume 111, Nº5, Novembro 2018

Minieditorial Garzon & Ribeiro Mundo real da ICP no sistema de saúde pública no rio de janeiro Arq Bras Cardiol. 2018; 111(5):731-732 1. Mansur, AP, Favarato, D. Mortalidade por doenças cardiovasculares no Brasil e na regiãometropolitana de São Paulo: atualização 2011. Arq Bras Cardiol. 2012; 99(2):755-61. 2. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4(13):256. 3. Bovet P, Paccaud, F. Cardiovascular disease and the changing face of global public health: a focus on lowandmiddle income countries. Publ Health Rev. 2012;33(2):397-415. 4. World Health Organization.(WHO). Global status report on noncommunicable diseases 2010. Burden:mortality, morbidity and risk factors. Geneva;2010. P.9-31. 5. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959-68. 6. Joshi R, Jan S, Wu Y, MacMahon S. Global inequalities in access to cardiovascular health care: our greatest challenge. J Am Coll Cardiol. 2008;52(23):1817-25. 7. SouzaeSilvaCG,KleinCH,GodoyPH,SalisLHA,SouzaeSilvaNA.Sobrevida em até 15 anos de homens e mulheres após intervenção coronariana percutânea paga pelo Sistema Único de Saúde no Estado do Rio de Janeiro, em 1999-2010. Arq Bras Cardiol. 2018; 111(4):553-561. 8. Weaver WD, Reisman MA, Griffin JJ, Buller CE, Leimgruber PP, Henry T, et al. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet. 2000;355(9222):2199-203. 9. BodenWE, O’Rourke RA, Teo KK, Hartigan PM, MaronDJ, KostukWJ, et al; COURAGE Trial Research Group. Optimal medical therapy with or without ICP for stable coronary disease. N Engl J Med. 2007;356(15):1503-16. 10. SedlisSP,HartiganPM,TeoKK,MaronDJ,Spertus JA,ManciniGB,etal.Effect of ICP on long-term survival in patients with stable ischemic heart disease. N Engl J Med. 2015;373(20):1937-46. 11. Rothwell PM. External validity of randomised controlled trials: “To whom do the results of this trial apply?”. Lancet. 2005;365(9453):82-93. 12. Tarride JE , Lim M, DesMeules M, Luo W, Burke N, O´Reilly D,et al. A review of the cost of cardiovascular disease. Can J Cardiol. 2009;25(6):195-202. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 732